Johnson & Johnson Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Johnson & Johnson yıllık ortalama 6.8% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 9.7% annual. Gelirler growing yılda ortalama 1.6% oranında artmaktadır. Johnson & Johnson'in özkaynak karlılığı 25.9% ve net marjı 21.8%'dir.
Anahtar bilgiler
6.82%
Kazanç büyüme oranı
9.54%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.95% |
| Gelir büyüme oranı | 1.65% |
| Özkaynak getirisi | 25.92% |
| Net Marj | 21.83% |
| Son Kazanç Güncellemesi | 29 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.Anlatı Güncellemesi • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Seeking Alpha • Apr 17
Johnson & Johnson: Why I See Downside Ahead
Summary Johnson & Johnson only slightly raised its 2026 financial guidance. So JNJ expects its operational sales to be between $99.7 billion and $100.7 billion, up from $99.5 billion to $100.5 billion. In my view, this is due to the sharp decline in demand for Stelara, JNJ's former "cash cow" in the immunology franchise. Moreover, JNJ's acquisition of Intra-Cellular Therapies for $14.6 billion doesn't meet my expectations, as Caplyta sales grew by only 8.4% quarter-on-quarter to $270 million. Further in this article, you'll learn about additional reasons why I believe Johnson &Johnson's risk/reward profile is still unattractive. Read the full article on Seeking AlphaAnlatı Güncellemesi • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
Yeni Anlatı • Mar 30
Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution
Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.Anlatı Güncellemesi • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
Yeni Anlatı • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.Anlatı Güncellemesi • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Anlatı Güncellemesi • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.Anlatı Güncellemesi • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
Yeni Anlatı • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.Anlatı Güncellemesi • Dec 19
JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook
Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.Anlatı Güncellemesi • Dec 05
JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance
The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.Anlatı Güncellemesi • Nov 21
JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance
Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.Anlatı Güncellemesi • Nov 05
JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance
Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.Anlatı Güncellemesi • Oct 22
Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments
Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Johnson & Johnson nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 29 Mar 26 | 96,362 | 21,040 | 24,003 | 14,967 |
| 28 Dec 25 | 94,193 | 26,804 | 23,130 | 14,665 |
| 28 Sep 25 | 92,149 | 25,119 | 22,742 | 15,711 |
| 29 Jun 25 | 90,627 | 22,661 | 22,211 | 16,991 |
| 30 Mar 25 | 89,331 | 21,810 | 21,906 | 16,915 |
| 29 Dec 24 | 88,821 | 14,066 | 21,952 | 17,232 |
| 29 Sep 24 | 87,696 | 14,767 | 21,290 | 16,414 |
| 30 Jun 24 | 86,576 | 16,382 | 21,050 | 14,909 |
| 31 Mar 24 | 85,648 | 17,072 | 20,640 | 15,172 |
| 31 Dec 23 | 85,159 | 13,326 | 20,166 | 15,085 |
| 01 Oct 23 | 83,703 | 12,421 | 19,648 | 14,315 |
| 02 Jul 23 | 82,348 | 12,422 | 19,323 | 14,353 |
| 02 Apr 23 | 77,458 | 10,730 | 17,993 | 14,128 |
| 01 Jan 23 | 79,990 | 16,370 | 19,078 | 14,135 |
| 02 Oct 22 | 84,855 | 17,879 | 21,037 | 15,145 |
| 03 Jul 22 | 88,197 | 17,236 | 22,197 | 15,082 |
| 03 Apr 22 | 94,880 | 19,830 | 24,430 | 14,998 |
| 02 Jan 22 | 78,740 | 17,801 | 19,506 | 14,277 |
| 03 Oct 21 | 91,446 | 17,880 | 23,364 | 14,026 |
| 04 Jul 21 | 89,190 | 17,767 | 22,852 | 13,444 |
| 04 Apr 21 | 84,214 | 15,115 | 21,817 | 12,757 |
| 03 Jan 21 | 82,584 | 14,714 | 21,731 | 12,159 |
| 27 Sep 20 | 80,856 | 16,986 | 21,681 | 11,359 |
| 28 Jun 20 | 80,503 | 15,185 | 21,625 | 11,118 |
| 29 Mar 20 | 82,729 | 17,166 | 22,185 | 11,077 |
| 29 Dec 19 | 82,059 | 15,119 | 21,885 | 11,355 |
| 29 Sep 19 | 81,706 | 14,151 | 21,957 | 11,347 |
| 30 Jun 19 | 81,325 | 16,332 | 22,191 | 11,256 |
| 31 Mar 19 | 81,593 | 14,679 | 22,437 | 11,229 |
| 30 Dec 18 | 81,581 | 15,297 | 22,540 | 10,775 |
| 30 Sep 18 | 81,382 | 1,542 | 22,454 | 11,194 |
| 01 Jul 18 | 80,684 | 1,372 | 22,300 | 11,271 |
| 01 Apr 18 | 78,693 | 1,245 | 21,758 | 10,928 |
| 31 Dec 17 | 76,450 | 1,300 | 21,520 | 10,594 |
| 01 Oct 17 | 74,361 | 15,827 | 20,600 | 9,591 |
| 02 Jul 17 | 72,531 | 16,335 | 20,012 | 9,184 |
| 02 Apr 17 | 72,174 | 16,505 | 20,020 | 9,152 |
| 01 Jan 17 | 71,890 | 16,540 | 19,793 | 9,143 |
| 02 Oct 16 | 71,595 | 15,941 | 20,527 | 9,319 |
| 03 Jul 16 | 70,877 | 15,027 | 20,836 | 9,295 |
| 03 Apr 16 | 70,182 | 15,546 | 21,044 | 9,160 |
| 03 Jan 16 | 70,074 | 15,409 | 21,203 | 9,046 |
| 27 Sep 15 | 70,517 | 14,715 | 21,134 | 8,817 |
| 28 Jun 15 | 71,882 | 16,106 | 21,521 | 8,686 |
Kaliteli Kazançlar: JNJ yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: JNJ 'nin mevcut net kar marjları (21.8%) geçen yılın (24.3%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: JNJ şirketinin kazancı son 5 yılda yılda 6.8% oranında arttı.
Büyüme Hızlandırma: JNJ 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.
Kazançlar vs. Sektör: JNJ geçtiğimiz yıl negatif kazanç büyümesine ( -3.2% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( -5% ) karşılaştırmayı zorlaştırıyordu.
Özkaynak Getirisi
Yüksek ROE: JNJ 'nin Özsermaye Getirisi ( 25.9% ) yüksek olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 21:12 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/29 |
| Yıllık Kazançlar | 2025/12/28 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Johnson & Johnson 53 Bu analistlerden 23, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |